UNSPSC 51342802: Atevirdine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C21H25N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, N24015WC6D chemically known as piperazine, 1-(3-(ethylamino)-2-pyridinyl)-4-((5-methoxy-1h-indol-2-yl)carbonyl)-, monomethanesulfonate but generally known as atevirdine, which bears US NIH Compound Identifier 60848. European Medicines Agency schedules Atevirdine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05591MIG.

UNSPSC 51342802 Atevirdine is a Commodity code whose recent state and local procurement activity focuses on pharmaceutical products, naloxone, and medical supplies rather than the specific active pharmaceutical ingredient named in the code's taxonomy entry. State and local governments are buying naloxone rescue kits, safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, medical and first aid supplies for emergency response, and direct-to-manufacturer prescription fulfillment capabilities under this code designation. Issuing bodies include county health departments, state health and human services commissions, municipal fire and rescue divisions, and multistate cooperative purchasing alliances. Work being solicited ranges from commodity procurement of off-the-shelf medical and pharmaceutical products to strategic market intelligence gathering around alternative pharmacy benefit and direct-contracting models.

Geographic activity centers on Florida and Minnesota, with additional involvement from Texas and Oregon through multistate cooperative frameworks. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually (posted June 30, 2026, due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies intended for the Tampa Fire Department Rescue Division—169 line items with an estimated contract value of $700,000.00, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount (posted March 25, 2026, due March 13, 2026)—the Minnesota Department of Administration's RFP through MMCAP for generic multi-source pharmaceuticals and OTC products with an effective date of July 1, 2026 (proposals due March 26, 2026), and the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs (posted April 3, 2026, response due April 3, 2026). The Texas RFI represents preliminary market research rather than a formal solicitation and signals upstream interest in alternative pharmaceutical supply-chain arrangements among state agencies.